Part 1 of the study evaluates reduction in urine protein: creatinine ratio, and part 2 of the study evaluates the number of patients achieving complete remission when on the bruton tyrosine kinase inhibitor for primary membranous nephropathy.
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-escalation
/PRNewswire/ Novartis today announced the introduction of T-Charge™, the company s next-generation CAR-T platform that will serve as the foundation for.
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.